nystatin oral
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
652
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
March 28, 2026
Boron's Double Edge-Antibiotics, Toxins, and the Fine Line Between Them.
(PubMed, Molecules)
- "Examples include polyene macrolide antibiotics such as amphotericin B, fungichromin, and nystatin, as well as tetracyclines, rifamycins, and macrolides such as sorangicin A, where boron coordination may affect solubility, aggregation, ionophoric behavior, and biological selectivity. Similar chemistry is observed in marine neurotoxins and polyether toxins-including tetrodotoxin, saxitoxin derivatives, azaspiracids, pectenotoxins, ciguatoxins, and gambierones-whose hydroxyl-rich frameworks enable reversible interactions with boron species present in seawater...By framing boron as a molecular "double edge," this review integrates chemical, biological, and environmental perspectives to highlight how boron coordination can simultaneously enhance antimicrobial activity while influencing toxicity and ecological persistence. Recognizing the role of boron in shaping the activity of natural products provides new insight into antibiotic function, toxin behavior, and the..."
Journal • Review
March 27, 2026
Synthesis and biological profiling of novel quinoline-thiadiazole-thiazolone scaffolds as antimicrobial agents.
(PubMed, Future Med Chem)
- "Streptomycin, ciprofloxacin, and nystatin were used as reference drugs. Molecular docking studies supported these results by revealing favorable ligand-protein interactions for the most active derivatives. These findings demonstrate that quinoline-thiadiazole-thiazolone hybrids represent promising scaffolds for further optimization toward the development of novel antimicrobial agents."
Journal • Infectious Disease
March 25, 2026
Repurposing an Antifungal Drug as an Effective Insulin Aggregation Inhibitor.
(PubMed, Chem Asian J)
- "To prevent insulin aggregation, here we repurposed an antifungal drug called Nystatin (Nys) identified through a virtual screening of 5500 FDA-approved drugs...The efficacy of Nys-treated formulations in maintaining glycemic control was further validated in a diabetic rat model. Thus, this FDA-approved drug has the potential to be used in commercial insulin formulations to maintain stability and activity while preventing its aggregation for an extended period."
Journal • Diabetes • Metabolic Disorders • IR
March 20, 2026
Serial Coincubation Enrichment Technique (SCET): Rapid isolation of bacterial biocontrol agents.
(PubMed, MethodsX)
- "The final suspension was serially diluted and spread on nutrient agar containing nystatin...• SCET setup mimics the rhizomicrobiome or classical dual assay, where already existing pathogens interact with the antagonistic bacteria of the rhizosphere. • Samples can be screened by comparing sole fungal growth in the medium against the fungal growth in a final enriched co-incubated setup."
Journal
March 17, 2026
Imanixil-mediated disruption of lipid trafficking impairs hepatic hemoglobin clearance in Sickle cell Disease
(THSNA 2026)
- "Moreover, using a small molecule inhibitor screen we further demonstrated that Hbs internalizes to LSECS through a slow, pH-dependent, lipid-dependent fluid-phase endocytic mechanism, where lipid supplementation significantly enhances Hb uptake and lipid depletion through simvastatin, nystatin, or the cholesterol-lowering agent Imanixil significantly impairs endothelial Hb internalization. These findings demonstrate that both LSECs and Kupffer cells depend on lipid-mediated endocytic pathways for efficient Hb clearance, establishing lipid availability as a major regulator of hepatic Hb regulation. Also, this study identifies lipid trafficking disruption as a mechanistic barrier to Hb detoxification and provides a foundation for future studies aimed at defining molecular lipid–endocytic pathway regulation and developing therapeutic strategies to mitigate hemolysis-associated liver injury in SCD. No part of this publication may be reproduced, distributed, or transmitted..."
Genetic Disorders • Hematological Disorders • Hepatology • Inflammation • Liver Failure • Sickle Cell Disease
March 17, 2026
Randomized controlled clinical trial of the impact of combined application of rhamnosus probiotics and oral nystatin on the colonization of intestinal Candida albicans in low birth weight neonates <2,500 grams.
(PubMed, GMS Hyg Infect Control)
- "This study was a randomized controlled clinical trial conducted on 104 infants born weighing <2,500 grams at Mohammad Kermanshahi Hospital in Kermanshah in 2021-22. The concurrent use of Rhamnosus probiotics and oral Nystatin can lead to a reduction of positive C. albicans stool culture results, average time for certain variables such as the onset of nutrition, time to reach 100 ml/kg of milk intake per day, NPO days, total NPO time during hospitalization, episodes of intolerance until discharge, and duration of hospitalization in infants weighing <2,500 grams. Hence, their simultaneous administration is recommended for these neonates."
Clinical • Journal
March 17, 2026
Limonene and carvacrol combined with drugs that inhibit ergosterol synthesis are potent against Leishmania major.
(PubMed, Naunyn Schmiedebergs Arch Pharmacol)
- "In this study, we report the effects of combinations of the monoterpenes limonene (Lim) and carvacrol (Car) with drugs targeting ergosterol biosynthesis, namely nystatin (Nys), tioconazole (Tio), and rosuvastatin (Ros), on Leishmania major, their cytotoxicity on macrophages, and we evaluate their synergism and mechanisms of action. Changes in parasite membrane integrity were also observed, which may be linked to the interaction of nystatin with the enzyme 14-alpha demethylase, along with an increase in TNF-α expression and a reduction in IL-10 and IL-6 levels. These results suggest that the combination of Lim-Car with Nys (3:2) may exert a summative effect through multiple biochemical pathways and warrants further investigation as a potential combined therapy with antileishmanial activity."
Journal • Infectious Disease • IL10 • IL6 • TNFA
March 13, 2026
A near-infrared mitochondrial-targeting viscosity fluorescent probe for studying autophagy and apoptosis in cancer cells.
(PubMed, Spectrochim Acta A Mol Biomol Spectrosc)
- "All the results confirmed that the probe BFD can sensitively monitor the fluctuations in mitochondrial viscosity, making it a powerful tool to visually evaluate the autophagy and apoptotic effects of cancer cells. This capability provides a promising strategy for early diagnosis of cancer and evaluating treatment efficacy, thereby contributing to more precise treatment monitoring."
Journal • Oncology
February 02, 2026
A Case of Disseminated Nocardiosis in a Heart Transplant Recipient
(ISHLT 2026)
- "He was induced with basiliximab (BAS) as a renal sparing strategy and maintained on tacrolimus, mycophenolate, and prednisone. OIP consisted of nystatin, valganciclovir, and atovaquone in lieu of TMP-SMX due to renal function...A CT chest identified nodular infiltrates concerning for disseminated infection, and empiric therapy was initiated with linezolid (LZD), imipenem-cilastatin, and TMP-SMX. TMP-SMX was later replaced with ciprofloxacin (CIP) due to AKI on CKD. The organism was subsequently identified as Nocardia pseudobrasiliensis and his antibiotic regimen was de-escalated to LZD and CIP based on susceptibilities with a planned duration of 6 months.Summary Studies have established that TMP-SMX is superior in preventing OI when compared to alternative agents such as atovaquone; furthermore, the incidence of Nocardiosis increases significantly in immunocompromised patients who are not on TMP-SMX. With implementation of the OPTN safety net program for kidney after..."
Clinical • Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Respiratory Diseases • Spindle Cell Sarcoma • Transplantation
March 10, 2026
Positivity rate of Aspergillus spp. in patients with tuberculosis-like symptoms in Yaoundé, Cameroon and antifungal resistance profile.
(PubMed, BMC Infect Dis)
- "Aspergillus spp. is present in the respiratory tract but often overlooked, and can lead to a misdiagnosis of tuberculosis. Although the very small number of isolates tested, Aspergillus spp. could be also affected to the antimicrobial resistance observed in recent years."
Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
March 08, 2026
Predicting antifungal concentrations that select for resistance: an enhanced approach to establish environmental thresholds.
(PubMed, Environ Int)
- "These ranged from 2.26x10-6 (voriconazole) to 2.16 mg/kg (nystatin). This type of data generation and analyses will inform discussions about targeted mitigation strategies to reduce the risk of selection for AFR, however, PNECR estimations can be improved with increased data for certain compounds, particularly agricultural fungicides. Preventing an increase in resistance is critical for reducing the risk posed to human health from exposure to environmental AFR."
Journal
March 06, 2026
Purring pathogen: Peritoneal dialysis peritonitis caused by Pasteurella multocida in a multicat household
(NKF-SCM 2026)
- "Empiric intraperitoneal vancomycin and cefepime were initiated with the addition of oral nystatin prophylaxis. Cultures were ultimately positive for Pasteurella multocida, with the plan to treat with intravenous (IV) ampicillin/sulbactam, followed by a 3-week course of oral amoxicillin/clavulanate and intraperitoneal cephalosporins...The patient remains infection-free while on hemodialysis at one-month follow-up. CONCLUSION This case illustrates the improtance of patient education in preventing peritoneal dialysis associated peritonitis, emphasizing the need to address pet exposure as an important modifiable risk factor"
Infectious Disease • Nephrology • Renal Disease
February 10, 2026
Patch testing in the diagnosis of delayed hypersensitivity reaction to nystatin
(AAAAI 2026)
- "Practice parameters recognize patch testing as a potentially useful modality in delayed hypersensitivity reactions characterized by morbiliform drug eruptions."
Immunology
February 27, 2026
Molecular Identification, Virulence Factors, and Antifungal Susceptibility Profiles of Candida Isolates from Clinical Samples of Intensive Care Patients.
(PubMed, Antibiotics (Basel))
- "Protease activity was positive in 52% of the isolates, phospholipase in 42%, hemolytic activity in 77%, and biofilm formation in 48%. Kruskal-Wallis analysis revealed no statistically significant interspecies differences in MIC distributions for amphotericin B, fluconazole, itraconazole, or nystatin (p > 0.05), although species-specific trends were observed, with higher fluconazole MICs in C. albicans and lower MIC values in C. tropicalis. Determining the distribution of Candida species, as well as their virulence factors and antifungal MIC profiles, is of great importance for developing appropriate treatment strategies and reducing related morbidity and mortality."
Journal • Candidiasis • Critical care • Hematological Disorders • Infectious Disease
February 26, 2026
Avian Candidiasis: A Comprehensive Review of Pathogenesis, Diagnosis, and Control.
(PubMed, Vet Sci)
- "Antifungal susceptibility investigations indicate that nystatin and amphotericin B are still very effective against most avian isolates and that resistance to the azoles is on the rise, especially with respect to the non-albicans Candida species...The knowledge gaps comprise the absence of avian-specific pharmacokinetic information, poor knowledge of species-species virulence phenotypes, and the lack of point-of-care diagnostics. The need to have integrated One Health surveillance systems is emphasized by the zoonotic potential of the avian Candida reservoirs."
Journal • Review • Candidiasis • Infectious Disease
February 26, 2026
Evaluation of Antimicrobials Incorporated into Artificial Saliva: Analysis Against Candida albicans.
(PubMed, J Funct Biomater)
- "This study aimed to evaluate the antimicrobial activity and determine the minimum inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) of AS formulations containing nystatin (Nys), chlorhexidine diacetate 98% (Chx), and silver nanoparticles (AgNp) against Candida albicans biofilm...Results demonstrated fungal load inhibition and a reduction in metabolic activity across all experimental groups (p < 0.05). Notably, AS + Nys, AS + Chx, and AS + AgNp 6 mM exhibited similar and significant inhibitory effects against C. albicans biofilm."
Journal • Xerostomia
February 26, 2026
Synergistic Antifungal Activity of Zinc Pyrithione and Nystatin against Multi-Drug-Resistant Candida (Candidozyma) auris: Evidence from In Vitro and In Vivo Models.
(PubMed, ACS Infect Dis)
- "Overall, the ZnPT + NYS combination demonstrated strong antifungal and antibiofilm activity against C. auris, with favorable safety outcomes. These findings support further investigation into its clinical potential as a treatment strategy against this emerging pathogen."
Journal • Preclinical • Infectious Disease
February 21, 2026
Viscosity-sensitive molecular rotors derived from cyclic chalcone for dual applications: Food monitoring and two-photon fluorescence lifetime imaging.
(PubMed, Food Chem)
- "Notably, YB-P, with its excellent photostability, achieved two-photon fluorescence lifetime imaging to track intracellular viscosity enhancement induced by nystatin and monensin. The high selectivity and stability of these probes provide an efficient tool for viscosity and polarity monitoring in complex systems."
Journal
February 21, 2026
Aloe emodin disrupts Candida albicans mitochondrial iron homeostasis against its hyphal development and oral candidiasis.
(PubMed, Appl Microbiol Biotechnol)
- "AE at 50-100 μg/mL administered via drinking water also significantly reduced fungal burden and tissue damage in an oropharyngeal candidiasis model, which is similar with clinical antifungal nystatin...• Aloe emodin downregulates the cAMP-PKA pathway to inhibit C. albicans hyphae. • Aloe emodin functions as a novel candidate for treating infections caused by C. albicans."
Journal • Candidiasis • Infectious Disease • Metabolic Disorders
February 16, 2026
Multi-targeted quinoline-sulfonamide-chalcone hybrids: novel candidates for anti-quorum sensing, anti-biofilm, and anticancer activities.
(PubMed, Bioorg Chem)
- "The studied compounds demonstrated promising biological activities, with QCS-h emerging as a lead candidate exhibiting broad-spectrum antimicrobial activity against both B. cereus, P. aeruginosa, and C. glabrata, with considerably lower IC50 values compared to the used standards, tetracycline and nystatin. The favorable ADME profiles further support the drug-like potential of these compounds. This integrative approach highlights the therapeutic promise of quinoline-sulfonamide-chalcone hybrids, particularly QCS-h, as multi-targeted agents for combating antimicrobial resistance and gastrointestinal malignancies, providing valuable insights for future rational drug design strategies."
Journal • Oncology • BCL2 • BIRC5 • EGFR
February 09, 2026
Integrative Structural Characterization of Candida glabrata Phosphoglycerate Kinase by Small-Angle X‑ray Scattering and AlphaFold: Implications for Therapeutic Targeting in Candidiasis.
(PubMed, ACS Omega)
- "Additionally, in order to evaluate its potential as a therapeutic target, we have performed molecular docking studies and enzymatic activity assays with pure Pgk using known antifungals amphotericin B, nystatin, and fluconazole and with the new plausible drugs, such as nilotinib and netupitant. In enzyme activity assays, a change in the kinetic parameter Km on the enzyme Pgk was observed in response to its interaction with nilotinib, netupitant, and amphotericin B. Thus, our results allow us to propose Pgk from C. glabrata as a possible therapeutic target against candidiasis. We consider it essential to design and develop new molecules specifically targeting this enzyme, which will contribute to a decrease in mortality associated with IC and improve the patient's quality of life."
Journal • Candidiasis
February 06, 2026
A Dual-Organelle Fluorescent Probe for Visualizing Intracellular Microviscosity Dynamics.
(PubMed, J Fluoresc)
- "Using multiple cellular stress models-including LPS stimulation, oleic-acid treatment, nystatin exposure, and erastin-induced ferroptosis-ZKW effectively reported viscosity elevations at the subcellular level. These results establish ZKW as a robust and versatile tool for probing microviscosity heterogeneity in living cells and for facilitating studies of viscosity-associated physiological and pathological processes."
Journal
February 05, 2026
Oral nystatin for the prevention of antibiotic-related fungal peritonitis in peritoneal dialysis patients: a systematic review and meta-analysis of randomized and observational studies.
(PubMed, JAC Antimicrob Resist)
- "Oral nystatin administered during antibiotic therapy was associated with a numerically lower rate of ARFP in PD patients, although all pooled estimates were based on unadjusted data and a limited number of events, thus precluding any certain causal inference. However, given its favourable safety profile and local action, nystatin may represent a valid candidate for a prophylactic strategy warranting further evaluation in contemporary, adequately powered randomized trials."
Journal • Observational data • Retrospective data • Review
February 04, 2026
Molecular Identification and Evaluation of Resistance to Antifungal Drugs in Candida Species Isolated From Diaper Rash of Neonates.
(PubMed, Health Sci Rep)
- "Nystatin, posaconazole, voriconazole, amphotericin B, ketoconazole, and clotrimazole showed high activity against all species (Minimum Inhibitory Concentration ≤ 0.125 µg/mL). The treatment of recurrent invasive candidiasis, needing repeated course of fluconazole or itraconazole, could be a risk factor for selecting resistant isolates. In addition, as the liposomal amphotericin B is no more commercialized in our country, a higher drug selection pressure for azoles may be expected in the future."
Journal • Candidiasis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Pediatrics
January 31, 2026
Emergence of Fusarium oxysporum infection in farmed Labeo rohita: Isolation, growth requirements, antifungal response, and pathogenic potential.
(PubMed, Vet Res Commun)
- "Antifungal susceptibility testing indicated that none of amphotericin B, ketoconazole, itraconazole, clotrimazole, and nystatin produced zones of inhibition against the fungal isolate. In contrast, the fungus exhibited sensitivity to sodium chloride and copper sulfate, with reduced radial growth at salinity levels exceeding 0.5% and CuSO4 concentrations above 25 ppm. Our findings confirm that the F. oxysporum strain is virulent to L. rohita, and highlights the potential utility of salinity and copper sulfate-based management strategies for control of this fungus in aquaculture."
Journal • Infectious Disease
1 to 25
Of
652
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27